Nanoparticles can improve the therapeutic performance of drugs by e.g. improving their pharmacokinetic properties and enhance the uptake by target cells. The understanding of interactions between nanoparticles and cells, as well as living organisms, is therefore a pivotal step in the development of nanomedicines.

In our group, we use a broad range of in vitro as well as in vivo assays to further characterize the behavior of nanoparticles. These assays are based on cell culture models such as the blood-brain barrier, invertebrate models prawn for high throughput screening (i.e. zebrafish embryos), and experimental animals such as mice and rats. Some examples are provided here: